Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants

AYTU BIOPHARMA, INC

Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.
Granted underwriters 30-day option to purchase up to additional 1,440,000 shares of common stock.
Net proceeds of approximately $12.9M (or $14.9M if option exercised) to be used for general corporate purposes and to exclusively commercialize EXXUA (gepirone) for major depressive disorder.
Offering expected to close June 9, 2025; Lake Street Capital Markets acting as sole book runner.
Maxim Group LLC acting as lead manager and Ascendiant Capital Markets as financial advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.